MS Treatment Denied by Insurance? How to Appeal

A multiple sclerosis diagnosis is life-altering enough without the added burden of fighting your insurance company for the treatment your neurologist prescribes. Yet MS patients face some of the highest rates of treatment denials in healthcare — particularly for disease-modifying therapies (DMTs), which are the cornerstone of MS management. These denials can cause dangerous treatment gaps that lead to irreversible neurological damage. If your MS treatment has been denied, understanding the appeal process and your legal rights is critical.

Why MS Treatment Gets Denied

Insurance companies deny MS treatments for several common reasons:

"Step therapy required." This is the most frequent denial reason for MS patients. Insurers require patients to try and fail cheaper, older DMTs (typically interferon beta or glatiramer acetate) before approving newer, more effective therapies like ocrelizumab, natalizumab, or oral agents such as fingolimod or dimethyl fumarate. Step therapy forces patients to endure months on less effective treatments — treatments their neurologist may have already determined are inappropriate for their disease course.

"Not medically necessary." The insurer's reviewer may claim that the prescribed DMT is not necessary for your specific type or stage of MS, or that a less expensive alternative would be equally effective. This denial often reflects formulary management rather than genuine clinical judgment.

"Experimental or investigational." Newer DMTs, combination therapies, or off-label uses of approved medications may be labeled experimental. Some insurers also deny treatments for progressive forms of MS (primary progressive or secondary progressive) that have fewer FDA-approved options.

"Specialty medication tier exclusion." Many DMTs are classified on the highest specialty tier of the insurer's formulary, subjecting them to higher copays, stricter Prior Authorization Denied: How to Appeal" class="auto-link">prior authorization requirements, or outright exclusion. Some plans exclude specific DMTs from their formulary entirely.

"Site of service restrictions." Infused DMTs like ocrelizumab or natalizumab require administration in a medical facility. Insurers may restrict where these infusions can be given, requiring hospital-based infusion centers instead of more convenient office-based settings, or vice versa.

Your Legal Rights

MS patients have powerful legal protections when appealing treatment denials:

ACA Section 2719 guarantees internal appeals and External Independent Review: Complete Guide" class="auto-link">external review. For MS treatment denials, expedited appeal rights are particularly important — if your neurologist certifies that delay would cause serious harm, the insurer must decide your appeal within 72 hours.

AAN Practice Guidelines. The American Academy of Neurology publishes comprehensive, evidence-based guidelines for the management of multiple sclerosis, including recommendations on DMT selection, switching, and escalation. AAN guidelines explicitly recommend that treatment decisions be individualized based on disease activity, patient factors, and the risk-benefit profile of each therapy — not dictated by step therapy protocols.

Mental Health Parity and Addiction Equity Act (MHPAEA). While MS is a neurological condition, some of its manifestations — including depression, cognitive impairment, and fatigue — overlap with mental health conditions. If your insurer applies more restrictive coverage criteria to neurological treatments than to comparable medical/surgical treatments, MHPAEA may provide additional grounds for appeal.

State step therapy override laws. A growing number of states have enacted step therapy reform laws that allow patients to bypass step therapy requirements if their physician determines the required step therapy drugs are clinically inappropriate, would cause harmful delay, or have already been tried and failed. Check whether your state has such a law — if so, it provides a direct legal basis for overriding the insurer's step therapy requirement.

ERISA Section 502 governs employer-sponsored plans and requires full and fair review of claims, including disclosure of the clinical rationale for denials and the right to submit additional evidence on appeal.

How to Appeal Step by Step

Step 1: Obtain the denial letter and the insurer's formulary and step therapy protocol. Understanding exactly what the insurer requires — and why they denied your specific treatment — is the foundation of your appeal. Request the insurer's clinical policy for MS DMTs, their formulary tier structure, and the specific step therapy sequence they require.

Step 2: Have your neurologist document why step therapy is inappropriate. Your neurologist should write a detailed letter explaining why the prescribed DMT is the appropriate first-line treatment for your specific case. This should include your MS type (relapsing-remitting, primary progressive, secondary progressive), disease activity (relapse frequency, MRI lesion burden, EDSS score), prognostic factors (age, lesion location, brain atrophy), and why the step therapy drugs are contraindicated or unlikely to be effective.

Step 3: Document any prior DMT trials. If you have previously tried other DMTs (even if not the specific ones the insurer requires), document the treatment dates, duration, clinical response, side effects, and reason for discontinuation. Failed prior therapy — even with a different drug than the insurer requires — strengthens the argument against further step therapy.

Step 4: Compile supporting clinical evidence. Include AAN practice guidelines, relevant clinical trial data for the prescribed DMT, and any evidence showing that treatment delay in MS leads to irreversible disability progression. The AAAAI/AAN consensus on early aggressive treatment for high-risk MS patients is particularly useful.

Step 5: File for a step therapy exception if your state allows it. If your state has a step therapy reform law, file the specific exception request required by that law. Your neurologist's documentation from Step 2 will support this request.

Step 6: Submit the appeal and request expedited review. MS treatment delays can cause irreversible neurological damage. Your neurologist should provide a statement certifying that delay poses a serious threat to your health, triggering the 72-hour expedited appeal timeline.

What to Include in Your Appeal Letter

• The denial letter with the specific denial reason and step therapy requirements identified
• Your neurologist's letter of medical necessity explaining the treatment rationale
• Your MS history: date of diagnosis, type, relapse history, current EDSS score
• MRI reports showing disease activity (new or enlarging lesions, gadolinium enhancement)
• Documentation of prior DMT trials and their outcomes
• AAN practice guidelines supporting individualized DMT selection
• Clinical trial data for the prescribed DMT relevant to your MS type
• State step therapy override law citation (if applicable)
• A statement from your neurologist that treatment delay poses serious health risk
• Citation to ACA Section 2719, expedited appeal rights, and external review rights

When to Escalate

Expedited external review should be requested immediately for MS treatment denials where delay could cause disease progression. Under federal law, expedited external review must be completed within 72 hours. The external reviewer will be a neurologist who specializes in MS and can evaluate whether the insurer's step therapy requirement is clinically appropriate.

State Department of Insurance complaint. File a complaint if the insurer is systematically denying MS treatments in violation of state step therapy reform laws, using non-neurologist reviewers, or failing to provide timely appeal decisions.

National MS Society advocacy. The National MS Society provides free advocacy assistance for patients facing insurance denials. Their case managers can help navigate the appeal process and connect you with legal resources.

Pharmaceutical manufacturer patient assistance. While not a long-term solution, most DMT manufacturers offer patient assistance programs that can provide the medication at reduced or no cost while your appeal is pending. This ensures you do not experience a treatment gap during the appeal process.

Legal representation. For ERISA-governed plans, an attorney specializing in insurance denials can evaluate whether the insurer's step therapy protocol violates ERISA's fiduciary duty requirements or constitutes a de facto benefit exclusion.

Frequently Asked Questions

Can my insurer force me to try and fail older MS drugs before approving newer ones? Step therapy is legal, but it is not absolute. AAN guidelines recommend individualized treatment selection based on disease characteristics, not a one-size-fits-all step therapy protocol. Many states have enacted step therapy reform laws that allow physicians to override step therapy requirements when clinically appropriate. Even without a state law, you can argue on appeal that rigid step therapy conflicts with the treating neurologist's evidence-based clinical judgment.

What if I experience a relapse while waiting for the appeal? Document the relapse thoroughly — including dates, symptoms, any ER visits or hospitalizations, steroid treatments, and residual deficits. A relapse during a treatment gap caused by the insurer's denial strengthens your appeal significantly and may support a claim for expedited review. Contact your neurologist immediately to update your appeal with this new information.

Does my insurer have to cover infusion costs separately from the drug? Yes. The drug cost and the infusion administration cost are separate charges. Your plan's coverage for each may differ (for example, the drug may be covered under the pharmacy benefit while the infusion is covered under the medical benefit). If either component is denied, each requires its own appeal.

What is the EDSS score and why does it matter for my appeal? The Expanded Disability Status Scale (EDSS) is a standardized measure of neurological disability in MS, ranging from 0 (normal) to 10 (death due to MS). Insurers often use EDSS scores in their clinical criteria for DMT approval. A higher EDSS score (indicating greater disability) may support approval for more aggressive treatment, while a lower score may be used to argue that aggressive treatment is premature. Your neurologist should document your EDSS score and explain its clinical significance.

Don't let your insurer's denial be the final word. Start your free appeal analysis — ClaimBack generates a professional, regulation-backed appeal letter in 3 minutes.